These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 30946323

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.
    Lee SE, Park HY, Lim SD, Han HS, Yoo YB, Kim WS.
    J Breast Cancer; 2020 Jun; 23(3):303-313. PubMed ID: 32595992
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment.
    Gompelmann D, Sinn K, Brugger J, Bernitzky D, Mosleh B, Prosch H, Geleff S, Blessing A, Tiefenbacher A, Hoetzenecker K, Idzko M, Hoda MA.
    J Cancer Res Clin Oncol; 2023 May; 149(5):1747-1754. PubMed ID: 35708777
    [Abstract] [Full Text] [Related]

  • 27. External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different.
    Dodson A, Parry S, Lissenberg-Witte B, Haragan A, Allen D, O'Grady A, McClean E, Hughes J, Miller K, Thunnissen E.
    J Pathol Clin Res; 2020 Apr; 6(2):138-145. PubMed ID: 31849189
    [Abstract] [Full Text] [Related]

  • 28. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
    Sinclair W, Kobalka P, Ren R, Beshai B, Lott Limbach AA, Wei L, Mei P, Li Z.
    Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
    [Abstract] [Full Text] [Related]

  • 29. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, Volante M, Buttitta F, Guerini-Rocco E, Righi L, D'antuono T, Scagliotti GV, Pinto C, De Rosa G, Papotti M.
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Hersom M, Jørgensen JT.
    Ther Drug Monit; 2018 Feb; 40(1):9-16. PubMed ID: 29084031
    [Abstract] [Full Text] [Related]

  • 39. Correlation of programmed death-ligand 1 expression in tumour cells between diagnostic small biopsies performed by radial EBUS and surgical specimens of peripheral lung cancer.
    Lachkar S, Gervereau D, Loïc P, De Marchi M, Morisse H, Dantoing E, Piton N, Thiberville L, Salaün M, Guisier F.
    BMJ Open Respir Res; 2024 Oct 15; 11(1):. PubMed ID: 39414327
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.